GAINESVILLE, Fla.--(BUSINESS WIRE)--With the patent expiration of Rogaine® and Propecia®, there is no longer a clear market leader in the $3.5B/year hair growth industry. Follicept™, developed by University of Florida spinoff Prometheon Pharma, is poised to fill that role in 2015 and challenge mediocre and often expensive drug, laser, and surgical treatments.
Follicept™ is considered a cosmetic, delivering extremely small yet effective doses of IGF-1, which naturally blocks the effects of testosterone on hair follicles. This creates a positive feedback loop, so a single dose of IGF-1 will remain active for many hair follicle life cycles. It avoids the “shedding” observed with Rogaine®, a common complaint of its users.
Help employers find you! Check out all the jobs and post your resume.
Follicept™ is considered a cosmetic, delivering extremely small yet effective doses of IGF-1, which naturally blocks the effects of testosterone on hair follicles. This creates a positive feedback loop, so a single dose of IGF-1 will remain active for many hair follicle life cycles. It avoids the “shedding” observed with Rogaine®, a common complaint of its users.
Help employers find you! Check out all the jobs and post your resume.